IL125735A - Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound - Google Patents
Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compoundInfo
- Publication number
- IL125735A IL125735A IL12573597A IL12573597A IL125735A IL 125735 A IL125735 A IL 125735A IL 12573597 A IL12573597 A IL 12573597A IL 12573597 A IL12573597 A IL 12573597A IL 125735 A IL125735 A IL 125735A
- Authority
- IL
- Israel
- Prior art keywords
- kinase
- glaucoma
- actin
- serine
- inhibitor
- Prior art date
Links
- 208000010412 Glaucoma Diseases 0.000 title 1
- 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 title 1
- 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 title 1
- 102000002727 Protein Tyrosine Phosphatase Human genes 0.000 title 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 108020000494 protein-tyrosine phosphatase Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/604,568 US5798380A (en) | 1996-02-21 | 1996-02-21 | Cytoskeletal active agents for glaucoma therapy |
PCT/US1997/002709 WO1997030701A2 (fr) | 1996-02-21 | 1997-02-21 | Compositions pharmaceutiques de traitement du glaucome |
Publications (2)
Publication Number | Publication Date |
---|---|
IL125735A0 IL125735A0 (en) | 1999-04-11 |
IL125735A true IL125735A (en) | 2003-09-17 |
Family
ID=24420147
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL12573597A IL125735A (en) | 1996-02-21 | 1997-02-21 | Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound |
Country Status (4)
Country | Link |
---|---|
US (2) | US5798380A (fr) |
AU (1) | AU2053597A (fr) |
IL (1) | IL125735A (fr) |
WO (1) | WO1997030701A2 (fr) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997023222A1 (fr) | 1995-12-21 | 1997-07-03 | Alcon Laboratories, Inc. | Utilisation de certains composes d'isoquinolinesulfonyle dans le traitement de glaucomes et d'ischemies oculaires |
US5980929A (en) * | 1998-03-13 | 1999-11-09 | Johns Hopkins University, School Of Medicine | Use of a protein tyrosine kinase pathway inhibitor in the treatment of retinal ischmemia or ocular inflammation |
US6028099A (en) * | 1998-03-13 | 2000-02-22 | John Hopkins University, School Of Medicine | Use of an inhibitor of the protein tyrosine kinase pathway in the treatment of choroidal neovascularization |
US5919813C1 (en) * | 1998-03-13 | 2002-01-29 | Univ Johns Hopkins Med | Use of a protein tyrosine kinase pathway inhibitor in the treatment of diabetic retinopathy |
EP1034793B1 (fr) | 1998-08-17 | 2005-10-26 | Senju Pharmaceutical Co., Ltd. | Medicaments preventifs/curatifs pour le glaucome |
CA2347519A1 (fr) * | 1998-10-13 | 2000-04-20 | Kyowa Hakko Kogyo Co., Ltd. | Agent pour le traitement de l'ophtalmopathie |
US6399655B1 (en) | 1998-12-22 | 2002-06-04 | Johns Hopkins University, School Of Medicine | Method for the prophylactic treatment of cataracts |
EP1259648A2 (fr) * | 2000-02-29 | 2002-11-27 | Alcon Laboratories, Inc. | Diagnostic et traitement du glaucome |
US7708711B2 (en) | 2000-04-14 | 2010-05-04 | Glaukos Corporation | Ocular implant with therapeutic agents and methods thereof |
US7867186B2 (en) | 2002-04-08 | 2011-01-11 | Glaukos Corporation | Devices and methods for treatment of ocular disorders |
US20020143284A1 (en) * | 2001-04-03 | 2002-10-03 | Hosheng Tu | Drug-releasing trabecular implant for glaucoma treatment |
AU2002258754B2 (en) | 2001-04-07 | 2006-08-17 | Glaukos Corporation | Glaucoma stent and methods thereof for glaucoma treatment |
US7431710B2 (en) | 2002-04-08 | 2008-10-07 | Glaukos Corporation | Ocular implants with anchors and methods thereof |
US7678065B2 (en) | 2001-05-02 | 2010-03-16 | Glaukos Corporation | Implant with intraocular pressure sensor for glaucoma treatment |
AU2002305400A1 (en) | 2001-05-03 | 2002-11-18 | Glaukos Corporation | Medical device and methods of use for glaucoma treatment |
US7331984B2 (en) | 2001-08-28 | 2008-02-19 | Glaukos Corporation | Glaucoma stent for treating glaucoma and methods of use |
US7163543B2 (en) * | 2001-11-08 | 2007-01-16 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
US7951155B2 (en) | 2002-03-15 | 2011-05-31 | Glaukos Corporation | Combined treatment for cataract and glaucoma treatment |
JP2006502700A (ja) * | 2002-03-27 | 2006-01-26 | セラテクノロジーズ、インコーポレイテッド | 高眼内圧および関連症状の予防および治療のための方法および化合物 |
US9301875B2 (en) | 2002-04-08 | 2016-04-05 | Glaukos Corporation | Ocular disorder treatment implants with multiple opening |
EP1501511A4 (fr) * | 2002-05-06 | 2006-06-07 | Univ Washington | Methodes de traitement du glaucome et d'autres etats induits par l'expression de nos-2 par inhibition de la voie egfr |
US20040167076A1 (en) * | 2003-02-14 | 2004-08-26 | Stamer W. Daniel | Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells |
CN1863779B (zh) * | 2003-10-15 | 2010-05-05 | 宇部兴产株式会社 | 吲唑衍生物 |
TW200526224A (en) * | 2003-12-22 | 2005-08-16 | Alcon Inc | Short form c-Maf transcription factor antagonists for treatment of glaucoma |
US7083783B2 (en) * | 2004-02-18 | 2006-08-01 | Wisconsin Alumni Research Foundation | Method for treating glaucoma |
WO2005079836A1 (fr) | 2004-02-18 | 2005-09-01 | Wisconsin Alumni Research Foundation | Methode de traitement de glaucome |
FR2879100B1 (fr) | 2004-12-09 | 2007-07-06 | Lionel Bueno | Compositions pour le traitement des pathologies oculaires de surface et de la retine |
EP1830853B1 (fr) * | 2004-12-27 | 2011-08-10 | Novartis AG | Analogues d'aminopyrazine servant a traiter le glaucome et d'autres maladies ou etats medies par rho kinase |
RU2407745C2 (ru) * | 2005-03-25 | 2010-12-27 | Инспайр Фармасьютикалз, Инк. | Цитоскелетоактивные соединения, композиция и применение |
US20060293378A1 (en) * | 2005-06-28 | 2006-12-28 | Mcintire Gregory | Method of lowering intraocular pressure |
ES2580108T3 (es) | 2005-07-11 | 2016-08-19 | Aerie Pharmaceuticals, Inc | Compuestos de isoquinolina |
US7867999B1 (en) | 2005-12-22 | 2011-01-11 | Alcon Research, Ltd. | Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions |
US7655662B2 (en) * | 2005-12-22 | 2010-02-02 | Alcon Research, Ltd. | (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure |
US7785624B2 (en) * | 2006-03-02 | 2010-08-31 | Inspire Pharmaceuticals, Inc. | Pharmaceutical latrunculin formulations |
US7414137B2 (en) * | 2006-03-23 | 2008-08-19 | Inspire Pharmaceuticals, Inc. | Process for the preparation of 3,4-disubstituted-thiazolidin-2-ones |
ES2729424T3 (es) | 2006-09-20 | 2019-11-04 | Aerie Pharmaceuticals Inc | Inhibidores de Rho cinasa |
WO2008061043A2 (fr) | 2006-11-10 | 2008-05-22 | Glaukos Corporation | Dérivation uvéosclérale et procédés pour son implantation |
US20100022517A1 (en) * | 2006-12-18 | 2010-01-28 | Richards Lori A | Ophthalmic formulation of rho kinase inhibitor compound |
AR064420A1 (es) * | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
US20080153903A1 (en) * | 2006-12-22 | 2008-06-26 | Alcon Manufacturing, Ltd. | Inhibitors of protein kinase c-delta for the treatment of glaucoma |
JP2008179624A (ja) | 2006-12-26 | 2008-08-07 | Santen Pharmaceut Co Ltd | ウレア構造を有する新規n−(2−アミノフェニル)ベンズアミド誘導体 |
US8455513B2 (en) | 2007-01-10 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-aminoisoquinoline compounds |
EP2133339A4 (fr) | 2007-03-28 | 2010-04-21 | Santen Pharmaceutical Co Ltd | Nouveau dérivé de (2-aminophényl)pyridinecarboxamide ayant une structure d'urée |
JP2008266322A (ja) | 2007-03-28 | 2008-11-06 | Santen Pharmaceut Co Ltd | ヒストン脱アセチル化酵素阻害作用を有する化合物を有効成分として含有する眼圧下降剤 |
US8455514B2 (en) * | 2008-01-17 | 2013-06-04 | Aerie Pharmaceuticals, Inc. | 6-and 7-amino isoquinoline compounds and methods for making and using the same |
US20100152646A1 (en) * | 2008-02-29 | 2010-06-17 | Reshma Girijavallabhan | Intravitreal injection device and method |
JP2010001289A (ja) | 2008-05-23 | 2010-01-07 | Santen Pharmaceut Co Ltd | ウレア構造を有する新規チオフェンジアミン誘導体 |
US8450344B2 (en) | 2008-07-25 | 2013-05-28 | Aerie Pharmaceuticals, Inc. | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds |
US20110223177A1 (en) * | 2008-09-09 | 2011-09-15 | University Of East Anglia | Treatment of fibrotic eye disorders |
ES2553827T3 (es) | 2009-05-01 | 2015-12-14 | Aerie Pharmaceuticals, Inc. | Inhibidores de mecanismo doble para el tratamiento de enfermedad |
US10206813B2 (en) | 2009-05-18 | 2019-02-19 | Dose Medical Corporation | Implants with controlled drug delivery features and methods of using same |
TW201102068A (en) * | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
WO2011137210A2 (fr) * | 2010-04-30 | 2011-11-03 | The Regents Of The University Of California | Modulation de l'élasticité du trabéculum cornéo-scléral |
EP4193907A1 (fr) | 2011-09-13 | 2023-06-14 | Glaukos Corporation | Capteur physiologique intraoculaire |
US9730638B2 (en) | 2013-03-13 | 2017-08-15 | Glaukos Corporation | Intraocular physiological sensor |
ES2852377T3 (es) | 2013-03-15 | 2021-09-13 | Aerie Pharmaceuticals Inc | Sales dimesilato de 4-(3-amino-1-(isoquinolin-6-ilamino)-1-oxopropan-2-il)bencilo, sus combinaciones con prostaglandinas y el uso de las mismas en el tratamiento de trastornos oculares |
FR3008698B1 (fr) * | 2013-07-18 | 2016-10-28 | Neuroptis Biotech | Procede pour la production d'un actif pharmaceutique |
EP3034081A1 (fr) * | 2014-12-18 | 2016-06-22 | Neuroptis Biotech | Traitement d'une inflammation de la glande tarsienne de la paupière |
US11925578B2 (en) | 2015-09-02 | 2024-03-12 | Glaukos Corporation | Drug delivery implants with bi-directional delivery capacity |
WO2017053885A1 (fr) | 2015-09-25 | 2017-03-30 | Glaukos Corporation | Implants lacrymaux à caractéristiques d'administration de médicament régulée et leurs procédés d'utilisation |
US9643927B1 (en) | 2015-11-17 | 2017-05-09 | Aerie Pharmaceuticals, Inc. | Process for the preparation of kinase inhibitors and intermediates thereof |
CA3005707C (fr) | 2015-11-17 | 2023-11-21 | Aerie Pharmaceuticals, Inc. | Procede de preparation d'inhibiteurs de kinase et de leurs intermediaires |
JP7003110B2 (ja) | 2016-04-20 | 2022-01-20 | ドーズ メディカル コーポレーション | 生体吸収性眼球薬物送達デバイス |
KR102568079B1 (ko) | 2016-08-31 | 2023-08-17 | 에어리 파마슈티컬즈, 인코포레이티드 | 안과용 조성물 |
CA3057872A1 (fr) | 2017-03-31 | 2018-10-04 | Aerie Pharmaceuticals, Inc. | Composes d'amide aryl cyclopropyl-amino-isoquinolinyl |
US11427563B2 (en) | 2018-09-14 | 2022-08-30 | Aerie Pharmaceuticals, Inc. | Aryl cyclopropyl-amino-isoquinolinyl amide compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4170398A (en) * | 1978-05-03 | 1979-10-09 | Koester Charles J | Scanning microscopic apparatus with three synchronously rotating reflecting surfaces |
US4343794A (en) * | 1980-05-06 | 1982-08-10 | Mt. Sinai | Method of reducing intraocular pressure with salts of vanadic acid |
US5306731A (en) * | 1985-06-14 | 1994-04-26 | Massachusetts Eye And Ear Infirmary | Method and products for treating the eye |
US4757089A (en) * | 1985-06-14 | 1988-07-12 | Massachusetts Eye And Ear Infirmary | Increasing aqueous humor outflow |
US4863912A (en) * | 1986-05-19 | 1989-09-05 | New York Medical College | Use of tetrahydrocortisol in glaucoma therapy |
US4997826A (en) * | 1986-05-19 | 1991-03-05 | New York Medical College | Tetrahydrocortisol in glaucoma therapy |
-
1996
- 1996-02-21 US US08/604,568 patent/US5798380A/en not_active Expired - Lifetime
-
1997
- 1997-02-21 IL IL12573597A patent/IL125735A/xx not_active IP Right Cessation
- 1997-02-21 WO PCT/US1997/002709 patent/WO1997030701A2/fr active Application Filing
- 1997-02-21 AU AU20535/97A patent/AU2053597A/en not_active Abandoned
-
1998
- 1998-02-11 US US09/022,228 patent/US6110912A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
WO1997030701A3 (fr) | 1998-02-26 |
IL125735A0 (en) | 1999-04-11 |
US6110912A (en) | 2000-08-29 |
US5798380A (en) | 1998-08-25 |
WO1997030701A2 (fr) | 1997-08-28 |
AU2053597A (en) | 1997-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL125735A (en) | Pharmaceutical compositions for the treatment of glaucoma comprising an inhibitor of serine-threonine kinase, tyrosine kinase or protein tyrosine phosphatase or an actin-disrupting compound | |
CA2216535A1 (fr) | Inhibiteurs de proteine kinase c | |
CA2237221A1 (fr) | Inhibiteur de la proteine kinase c | |
CA2137203A1 (fr) | Inhibiteurs de la proteine kinase c | |
HUP0103633A2 (hu) | Szubsztituált 3-cianokinolinok mint protein tirozin kinázok inhibitorai, eljárás a vegyületek előállítására és a vegyületeket tartalmazó gyógyászati készítmények | |
GEP20063885B (en) | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | |
WO2001044247A3 (fr) | Agents et methodes de traitement des maladies hyperplasiques | |
HUP0004490A2 (en) | Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threoning kinase inhibitors and pharmaceutical compositions containing them | |
WO2001019829A3 (fr) | Pyrazolopyrimidines en tant qu'agents therapeutiques | |
HUP0103520A3 (en) | Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors and pharmaceutical compositions containing them | |
AU6257798A (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
AU5759899A (en) | Hydroxyflavone derivatives as tau protein kinase 1 inhibitors | |
AU1774097A (en) | Pharmaceutical compositions for the treatment of rhinitis | |
CA2378428A1 (fr) | Utilisation d'antagonistes de cgrp et d'inhibiteurs de secretion cgrp servant a lutter contre les bouffees de chaleur de la menopause | |
ZA9811629B (en) | The use of MMP inhibitors for the treatment of ocular angiogenesis. | |
CA2284142A1 (fr) | Compositions contenant des acides lysophosphotidiques inhibant l'apoptose, et leurs utilisations | |
AU1189201A (en) | Therapeutic compositions including protein kinase c inhibitors | |
HUP0003679A3 (en) | Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases | |
WO2003051838A3 (fr) | Inhibiteurs de la proteine kinase | |
WO2001044235A3 (fr) | Agents et methodes de traitement des maladies hyperplasiques | |
AU5494298A (en) | Pharmaceutical compositions for the treatment of the eye | |
AU686084B3 (en) | Pharmaceutical compositions for the treatment of depressive disorders | |
HUP9903685A3 (en) | Use of olanzapine for the preparation of pharmaceutical compositions treating excessive aggression | |
CA2189567A1 (fr) | Composes bicycliques substitues, condenses et pontes, utilises comme agents therapeutiques |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
MM9K | Patent not in force due to non-payment of renewal fees |